<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01451580</url>
  </required_header>
  <id_info>
    <org_study_id>LD0411</org_study_id>
    <nct_id>NCT01451580</nct_id>
  </id_info>
  <brief_title>Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II Study of Pegylated Liposomal Doxorubicin (Lipo-Dox) Combined With Cyclophosphamide /5-Fluorouracil as Second Line Chemotherapy in the Treatment of Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TTY Biopharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TTY Biopharm</source>
  <brief_summary>
    <textblock>
      To determine the overall objective response rate of pegylated liposomal doxorubicin
      （Lipo-Dox）combined with cyclophosphamide/5-FU as second-line treatment in patients with
      metastatic breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipo-Dox</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically proved breast cancer with metastatic disease

        Exclusion Criteria:

          -  life expectancy less than 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hsien-Kun Chang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital, Lin-Kou Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CGMH</name>
      <address>
        <city>Linko</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang, AN</last_name>
      <phone>+8862-2545-3105</phone>
      <email>monicachang@tty.com.tw</email>
    </contact>
    <investigator>
      <last_name>Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2011</study_first_submitted>
  <study_first_submitted_qc>October 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2011</study_first_posted>
  <last_update_submitted>October 12, 2011</last_update_submitted>
  <last_update_submitted_qc>October 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2011</last_update_posted>
  <keyword>Phase II</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

